|November 28, 2012|
|09:31 EDT||WLP, ZBRA||House Energy and Commerce Committee to hold a hearing|
The Subcommittee on Health holds a hearing entitled, "Options to Combat Healthcare Waste, Fraud and Abuse" with participants Director Lavelle of Wellpoint and Senior Vice President Terzich of Zebra Technologies on November 28 at 10 am. Webcast Link
News For WLP;ZBRA From The Last 14 Days
|November 21, 2014|
|10:00 EDT||ZBRA||On The Fly: Analyst Upgrade Summary |
Today's noteworthy upgrades include: Best Buy (BBY) upgraded to Outperform from Market Perform at Telsey Advisory... BlackRock (BLK) upgraded to Outperform from Market Perform at Bernstein... Cerner (CERN) upgraded to Outperform from Market Perform at Cowen... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... Lockheed Martin (LMT) upgraded to Neutral from Sell at UBS... Teekay Offshore Partners (TOO) upgraded to Buy from Neutral at Citigroup... Trinity Industries (TRN) upgraded to Buy from Neutral at Longbow... Zebra Technologies (ZBRA) upgraded to Overweight from Neutral at JPMorgan... Ross Stores (ROST) upgraded to Hold from Sell at Maxim... St. Jude Medical (STJ) upgraded to Outperform from Market Perform at Cowen... Wolverine World Wide (WWW) upgraded to Buy from Neutral at DA Davidson... D.R. Horton (DHI) upgraded to Market Perform from Underperform at Raymond James... KB Home (KBH) upgraded to Market Perform from Underperform at Raymond James... Sony (SNE) upgraded to Overweight from Neutral at JPMorgan.
|06:10 EDT||ZBRA||Zebra Technologies upgraded to Overweight from Neutral at JPMorgan|
JPMorgan upgraded Zebra Technologies to Overweight citing a favorable risk/reward despite near-term integration risk from the Motorola enterprise business acquisition. The firm raised its price target for shares to $87 from $75.
|November 14, 2014|
|08:04 EDT||WLP||WellPoint, Boehringer Ingelheim announce first project under collaboration|
Boehringer Ingelheim Pharmaceuticals, WellPoint and HealthCore, announced that the companies are commencing a research project to identify and address unmet medical needs across populations of mutual interest. The first stage of the project will focus on non-valvular atrial fibrillation and will examine disease prevalence, treatment complications, such as hospital readmissions, and the use of evidence-based guidelines. This project is the first under the parties’ five-year research collaboration agreement, signed earlier this year. Information gathered through the NVAF project is intended to provide the basis for the collaborative development of healthcare interventions, which can be evaluated within WellPoint’s affiliated health plans and provider networks.
|November 12, 2014|
|08:58 EDT||WLP||Managed Care earnings risk low from King vs. Burwell, says Leerink|
Leerink believes the Supreme Court decision to the King vs. Burwell case carries low earnings risk for Managed Care companies. The case to determine the legality of Exchange subsidies administered by the Federal Government carries less than 2% and 3% of earnings risk for 2014 and 2015 estimates, respectively, Leerink believes. The firm says Humana (HUM) and Cigna (CI) are currently losing money on Exchanges, and thus could benefit from any Federal Exchange membership loss. Leerink lists Aetna (AET), Centene (CNC), WellPoint (WLP) and Molina Healthcare (MOH) as being most impacted.
|November 11, 2014|
|12:55 EDT||WLP||Workarounds to likely protect insurers from Supreme Court decision, says Wedbush|
Subscribe for More Information
|November 10, 2014|
|15:53 EDT||WLP||Credit Suisse to hold a conference|
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
|07:34 EDT||WLP||WellPoint has strong momentum heading into 2015, says UBS|
UBS said WellPoint has strong momentum across all business segments heading into 2015. The firm expects the company's national account business to grow and sees the company having earnings power from the public exchanges, Medicare, and Medicaid. UBS reiterates its Buy rating on WellPoint and raised its price target to $150 from $144.